Advanced Renal Cell Carcinoma Treatment Market size is projected to surpass USD 13 Billion by the end of 2035, witnessing around 6% CAGR during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of advanced renal cell carcinoma treatment was USD 6 Billion. The growth of the market can be attributed to the increasing cases of renal cancer amongst the population across the globe. A family history of renal cancer is the biggest cause of the such type of cancer. For instance, renal cell carcinoma (RCC) is a dangerous neoplasm that accounts for around 5% of worldwide cancer diagnoses and fatalities, and its global burden is expected to radically rise in the coming years. Moreover, high blood pressure, along with excessive smoking, and the increasing awareness amongst the people regarding early diagnosis and treatment of cancer, is estimated to boost the global advanced renal cell carcinoma treatment market growth over the forecast period.
In addition to these, factors that are believed to fuel the market growth of advanced renal cell carcinoma treatment include the rise in inactive and sedentary lifestyles throughout the world. As per the World Health Organization (WHO) report, physical inactivity is responsible for around 2 million deaths worldwide each year. Sedentary lifestyles are practiced by 60 to 85% of people worldwide, including both developed and developing countries, making it one of the most severe yet under-addressed public health issues of the present time. In addition to this, a surge in the availability of novel drugs and treatments is the major factor that is projected to spur market growth during the forecast period.
Growth Drivers
Growing Proportion of Geriatric Population– The term "geriatric population" refers to those who are 60 years of age or older. Getting older causes a progressive decline in physical and mental capacity, as well as an increased chance of disease and, eventually, death. Therefore, the growing proportion of the geriatric population is estimated to boost the market growth of advanced renal cell carcinoma treatment over the forecast period. Based on the World Health Organization statistics, by 2050, the world's population of adults aged 60 and above is estimated to be doubled (2.1 billion). The count of people aged 80 and more is predicted to triple between 2020 and 2050, reaching 426 million.
Worldwide Increasing Ratio of Smoking – For instance, the worldwide annual consumption of cigarettes is close to 6 trillion, which results in more than 9 million deaths and about USD 2.5 trillion in economic losses.
An Upsurge in Hypertension Cases – As per a report, globally, an estimated 1.28 billion persons aged 30-79 years have hypertension, with the majority (two-thirds) living in low- and middle-income nations.
Worldwide Increasing Healthcare Expenditure – Ascribed to the World Bank statistics, worldwide healthcare expenditure has increased from 9.4% in 2014 to 9.83% in 2019.
Novel Drugs and Therapeutic Approaches for Advanced Renal Cell Carcinoma – There are several types of research regarding novel drug discoveries and therapies that have been conducted to combat the fatalities of renal cell carcinoma. These novel cancer therapeutics drugs are such a boon that help a lot of individuals survive the deadly effects of renal cell carcinoma. For instance, Tyrosine kinase inhibitors, immune checkpoint inhibitors, and mTOR signaling inhibitors are presently authorized treatments for renal cell carcinoma (RCC). The development of drugs that target MET and hypoxia-inducible factor 2 as a result of a better understanding of the biology of clear cell and non-clear cell RCC, as well as current developments into the possibility of targeting immune pathways other than programmed death ligand 1 or cytotoxic T lymphocyte-associated protein 4 checkpoints. The research of combination treatments and an effort to employ a risk-adapted approach in treatment are two areas where drug development in RCC is evolving.
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~6% |
|
Base Year Market Size (2022) |
~ USD 6 Billion |
|
Forecast Year Market Size (2035) |
~ USD 13 Billion |
|
Regional Scope |
|
Treatment (Biologics, Radiation Therapy, Chemotherapy, Hormone, Vaccine Therapy)
The global advanced renal cell carcinoma treatment market is segmented and analyzed for demand and supply by treatment into biologics, radiation therapy, chemotherapy, hormone, vaccine therapy, and others. Out of these six types of segments, the biologics segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the increasing prevalence of renal cell carcinoma, along with its higher efficiency of biologics to target the disease while decreasing the side effects to normal cells in the body. Moreover, expanding the product pipeline, surging count of trials, and accelerating drug approval are also estimated for the expansion of the segment during the projected time frame. For instance, Exelixis launched the STELLAR-304 trial in 2022 to compare the effectiveness of sunitinib versus zanzalintinib in patients with advanced non-clear cell renal cell carcinoma. Moreover, the increasing number of scenarios for developing cost-effective biosimilars is another significant factor that is estimated to radically propel the growth of the biologics segment in the projected time frame.
End-user (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers)
The global advanced renal cell carcinoma treatment market is also segmented and analyzed for demand and supply by end-user into hospitals, cancer research institutes, ambulatory surgical centers, and others. Amongst these four segments, the hospitals segment is expected to garner a significant share. The growth of the segment can be attributed to the higher acceptance of hospitals across the globe. Patients prefer hospitals over surgical centers, as hospitals provide a wider range of treatment possibilities, which is estimated to boost segment growth.
Our in-depth analysis of the global market includes the following segments:
|
By Treatment |
|
|
By Route Of Administration |
|
|
By End-User |
|
North American Market Forecast
The North American advanced renal cell carcinoma treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035. The growth of the market can be attributed majorly to the increasing prevalence of renal cell carcinoma and other cancers in the region. For instance, in 2022, about 79,000 new cases of kidney cancer are expected to be diagnosed, out of which, 50,290 cases in men and 28,710 in women are anticipated to be diagnosed. Along with this, close to 13,920 deaths are anticipated to be caused by kidney cancer. Besides this, the rising adoption of advanced therapeutics, along with the surge in novel product approval are some major factors that are estimated to boost the market growth further during the projected time frame. In addition to this, the presence of significant key players is also anticipated to boost market growth during the forecast period.
APAC Market Statistics
The Asia Pacific advanced renal cell carcinoma treatment market, amongst the market in all the other regions, is projected to grow with a notable CAGR during the forecast period. The growth of the market can be attributed majorly to the increasing frequency of kidney cancer cases in the region, followed by the radical growth in the healthcare sector in the region. Moreover, an upsurge in the sedentary lifestyle of individuals is also projected to further fuel the growth of the advanced renal cell carcinoma treatment market in the APAC region during the forecast period.
Bristol Myers Squibb Company and Exelixis, Inc. reported three-year follow-up results from the Phase 3 CheckMate-9ER trial. Compared to sunitinib, Opdivo (nivolumab) and CABOMETYX (cabozantinib) have demonstrated sustained survival and response rates when used as a first-line treatment for advanced renal cell carcinoma (RCC).
Merck & Co., Inc’s anti-PD-1 therapy KEYTRUDA has been approved by FDA for use as adjuvant therapy in patients with renal cell carcinoma (RCC) at intermediate-high or high recurrence risk following nephrectomy, or following nephrectomy and metastatic resection.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?